The History of Celtek Bioscience: From Early SBIR Research to CB5005

TLDR: Celtek Bioscience history can be traced through several distinct records: a reported business start in March 2002, two NIH Phase I SBIR projects listed in 2003 and 2004, a patent application that led to a 2008 U.S. patent, and preclinical publications involving cell-penetrating or peptide-modified delivery systems from 2016 through 2020. Together, these records document a sustained research theme involving intracellular delivery, NF-κB-related biology, and experimental cancer models. They do not establish a clinically approved therapy, demonstrated patient benefit, or the current development status of CB5005.

A careful Celtek Bioscience history requires more than repeating an undated company narrative. Business profiles, award listings, patent documents, peer-reviewed literature, and current first-party pages answer different questions. The Celtek Bioscience website provides present-day corporate context, while dated external records help establish when particular projects, intellectual-property filings, and publications appeared.

The resulting timeline is informative but incomplete. It shows that research was proposed, funded, patented, or published at particular times. It does not show that every technical objective was achieved, that a patent claim was experimentally validated in people, or that a preclinical compound became an approved product.

Celtek Bioscience history at a glance

Period	Documented event	What the record establishes
March 2002	A Better Business Bureau profile reports a March 1 business start and March 19 incorporation date.	A reported starting point for the company; state filings would be preferable for definitive legal confirmation.
2003	A grant-award listing records NIH/NCI Phase I project 1R43CA099340-01, “Enhancement of Cancer Therapy by Inhibiting NF-kB.”	An early federally funded small-business research project focused on NF-κB-related cancer research.
2004	An archived listing records NIH/NIA Phase I project 1R43AG023361-01A1, “Peptide Inhibitor For Alzheimer's Disease Therapy.”	A second early-stage research award, not evidence of a clinically effective Alzheimer’s treatment.
2004–2008	A patent priority date, application, and eventual grant document apoptosis-related peptide compositions and methods.	A traceable intellectual-property record, not proof of safety or efficacy.
2016–2020	The literature record includes cell-penetrating and peptide-modified delivery studies conducted in preclinical systems.	Continued experimental work in cells, tumor spheroids, and mouse models rather than human clinical evidence.

2002: A reported business start

The earliest supplied date comes from a Better Business Bureau profile. It lists March 1, 2002 as the business start date and March 19, 2002 as the incorporation date for Celtek Bioscience, LLC. These dates provide a reasonable historical marker, but they should be attributed to the profile rather than treated as definitive legal findings. A state corporate filing would be the stronger source for the exact date and nature of formation.

That distinction matters in company histories. A business may begin operations, register a legal entity, obtain a license, or adopt a trade name on different dates. The available record supports describing Celtek as having a reported start in March 2002. It does not justify reconstructing unrecorded details about its original facilities, staffing, financing, or commercial capabilities.

2003–2004: Two Phase I SBIR research projects

The next documented phase involves two Small Business Innovation Research awards associated with Yao-Zhong Lin as principal investigator. These records are important because they identify specific research questions and connect them to dates and federal institutes. Their meaning must still be interpreted at the correct evidence level.

The 2003 NCI project and NF-κB

A 2003 SBIR/STTR award listing includes NIH/National Cancer Institute Phase I award 1R43CA099340-01, titled “Enhancement of Cancer Therapy by Inhibiting NF-kB.” It identifies Yao-Zhong Lin as principal investigator. A separate archived project listing reports the same project title and award number.

The title places inhibition of NF-κB at the center of the proposed work. It is evidence of the project’s research direction, but the award listing alone does not establish which inhibitor was ultimately developed, how well it performed, or whether the project met every technical objective. Those questions would require a final report, resulting publication, or other project-specific data.

The Phase I designation is also significant. NIH’s explanation of the SBIR and STTR program phases describes Phase I as the stage used to establish technical merit, feasibility, and commercial potential. It should therefore be understood as funded early-stage investigation. An award indicates that a proposed research program received support; it is not regulatory approval or confirmation that a therapeutic concept works in patients.

The 2004 NIA peptide-inhibitor project

An archived award listing identifies a 2004 NIH/National Institute on Aging Phase I SBIR project, 1R43AG023361-01A1, titled “Peptide Inhibitor For Alzheimer's Disease Therapy.” Yao-Zhong Lin is again listed as principal investigator.

This record broadens the documented early research beyond the cancer-focused project. It also illustrates why historical titles require careful wording. “For Alzheimer's Disease Therapy” states the intended research application in the award title. It does not mean that the resulting peptide was shown to treat Alzheimer’s disease in people. The supplied record does not establish completed clinical development, patient outcomes, or regulatory authorization.

Taken together, the 2003 and 2004 listings show an early emphasis on peptide inhibitors and intracellular disease-related targets. They do not, by themselves, reveal whether the two projects used the same molecular design, produced the same candidate, or contributed directly to the later compound identified as CB5005. Establishing such continuity would require sequence-level, patent, or publication evidence.

2004–2008: The apoptosis-related patent record

The most detailed intellectual-property milestone in the supplied record is U.S. Patent 7,408,022, titled “Composition and method for increasing apoptosis in cancer cells.” Its record identifies November 9, 2004 as the priority date and November 9, 2005 as the filing date for U.S. application 11/270,295. The patent was granted on August 5, 2008. Celtek Bioscience is identified as the original assignee, with Yao-Zhong Lin and Claudia Budu named as inventors.

The patent is historically useful because it documents named inventors, an assignee, filing events, and disclosed compositions and methods. Readers can examine the U.S. patent record for the apoptosis-related invention to distinguish bibliographic facts from the scientific and legal scope of its claims.

A patent nevertheless answers a different question from an efficacy study. It records disclosed intellectual property that was examined and granted under patent law. It does not demonstrate that a composition is safe, clinically effective, commercially available, or approved by a regulator. Nor does the historical grant alone establish the present enforceability or commercial status of the rights.

The patent also should not be used as a substitute for direct experimental verification of a peptide’s identity or mechanism. Claims about an exact CB5005 sequence, intracellular localization, biochemical target, or functional potency should be traced to the relevant patent passages and original experiments before being stated as established facts.

2016–2020: The later preclinical publication record

Later publications move the record from awards and patent documents into experimental delivery research. The available studies concern cell-penetrating or peptide-modified systems combined with established drug cargos. The key interpretive issue is the model: the supplied evidence concerns laboratory and animal experiments, not clinical trials in patients.

A 2016 nucleus-penetrating peptide publication

The supplied literature trail includes a 2016 publication titled “Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma,” associated with DOI 10.1016/j.actbio.2016.06.031. The title indicates a peptide-delivery and drug-combination research question. Because the supplied record is an aggregator rather than the original article, detailed statements about the peptide, methods, authorship, affiliations, results, or magnitude of effect should await verification from the paper itself.

Even at the level of the title, “synergistic treatment” should be read in experimental context. In preclinical literature, treatment can refer to exposing cultured cells or administering an intervention in an animal model. It does not necessarily describe medical treatment of people.

CB5005-modified liposomes in preclinical glioblastoma models

A scholarly review of nanoscale drug-delivery systems in glioblastoma discusses 2018 work involving CB5005-modified, doxorubicin-containing liposomes. The review describes experimental evaluation using cells, tumor spheroids, and mouse xenograft models.

These models address different stages of a delivery hypothesis. Cell experiments can measure association, uptake, toxicity, or downstream responses under controlled conditions. Tumor spheroids introduce a three-dimensional barrier that may reveal penetration differences not visible in a flat cell culture. Mouse xenografts add whole-animal exposure and tumor-model complexity. None of those systems, individually or together, establishes safety or effectiveness in humans.

The more important distinction is between uptake and productive intracellular delivery. A peptide-decorated liposome may associate with cells or enter endocytic vesicles without releasing enough active cargo into the cytosol or another required compartment. A convincing delivery mechanism therefore requires assays that separate surface binding, internalization, endosomal localization, cargo release, target engagement, and the resulting phenotype.

A 2020 Celtek-affiliated lung-cancer study

A 2020 Molecular Pharmaceutics article was titled “Treatment of Lung Cancer by Peptide-Modified Liposomal Irinotecan Endowed with Tumor Penetration and NF-κB Inhibitory Activities.” Its PubMed record identifies Yao-Zhong Lin as an author and includes a Celtek Bioscience affiliation. The reported research used A549 cells and mouse A549 xenografts.

This publication connects the later research record to Celtek through an author affiliation and continues the themes of peptide modification, tumor penetration, drug delivery, and NF-κB-related activity. It remains preclinical evidence. A549 cells are a laboratory cell model, while a mouse xenograft is an animal model in which human-derived tumor cells are grown in mice. Results in either model can support further investigation but cannot establish patient benefit, human dosing, clinical safety, or regulatory approval.

What the historical record supports

The sources support a coherent but limited account of Celtek’s research trajectory. The company had a reported business start in 2002; award records document Phase I projects in 2003 and 2004; patent activity beginning in 2004 led to a U.S. grant in 2008; and later publications examined peptide-enabled delivery systems in preclinical cancer models. A current first-party history page from Celtek Peptides also places Celtek Bioscience within a continuing corporate research narrative, although that page is corporate context rather than independent corroboration.

Supported: dated evidence of early Phase I small-business research projects.
Supported: a U.S. patent record naming Celtek Bioscience as original assignee.
Supported: a later publication record involving peptide-modified delivery, NF-κB-related activity, cell models, tumor spheroids, and mouse xenografts.
Not established: that either SBIR project achieved all of its proposed objectives.
Not established: that a patent grant proved biological efficacy or clinical usefulness.
Not established: that CB5005 completed human trials, received regulatory approval, benefited patients, or became a marketed therapy.
Not established: the current operational status of any historical therapeutic program.

How to evaluate future claims about CB5005

Any update to this history should classify evidence before drawing conclusions. A grant database can confirm funding and project metadata. A patent can establish filing history and disclosed claims. An original paper can describe experiments and results. A trial registry can document a registered human study, while a regulator is the appropriate authority for approval status. These records are complementary, not interchangeable.

For CB5005 specifically, the most informative next evidence would include direct verification of the compound’s sequence and naming across the patent and original papers, assays that distinguish cellular uptake from cytosolic delivery, direct target-engagement data, and clearly documented current program status. If a human study were claimed, it would need confirmation through a clinical-trial record and resulting clinical data rather than inference from cell or xenograft experiments.

Conclusion

The documented history of Celtek Bioscience is best understood as a research timeline rather than a clinical success story. Available records trace an arc from reported formation in 2002, through early NIH Phase I projects and apoptosis-related patent development, to later preclinical studies of peptide-modified delivery systems. The evidence is strongest for the existence and timing of those activities. It is not evidence of an approved or patient-proven CB5005 therapy.

The practical next step for anyone extending this history is to match each claim to the record capable of proving it: state filings for legal formation, NIH records for award details, original papers for experimental findings, patent documents for intellectual-property history, and regulatory or trial databases for any claimed clinical transition.